Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Liver Int. 2024 Nov;44(11):2904-2914. doi: 10.1111/liv.16056. Epub 2024 Aug 13.
The role of histamine in advanced chronic liver disease (ACLD) is poorly understood. We investigated plasma histamine levels across ACLD stages and their prognostic value.
We included patients with evidence of ACLD, defined by portal hypertension (hepatic venous pressure gradient [HVPG] ≥6 mmHg) and/or a liver stiffness measurement by transient elastography ≥10 kPa, who underwent HVPG measurement between 2017 and 2020. Acute-on-chronic liver failure (ACLF) and/or liver-related death were defined as composite endpoint.
Of 251 patients, 82.5% had clinically significant portal hypertension (median HVPG: 17 mmHg [interquartile range (IQR) 12-21]) and 135 patients (53.8%) were decompensated at baseline. Median plasma histamine was 8.5 nmol/L (IQR: 6.4-11.5), 37.1% of patients showed elevated values (>9.9 nmol/L). Histamine levels did not differ significantly across Child-Turcotte-Pugh (CTP) stages nor strata of model for end-stage liver disease (MELD) or HVPG. Histamine levels correlated with markers of circulatory dysfunction (i.e. sodium, renin and aldosterone). During a median follow-up of 29.2 months, 68 patients developed ACLF or liver-related death. In univariate as well as in multivariate analysis (adjusting for age, sex, HVPG as well as either MELD, clinical stage, and serum albumin or CTP and serum sodium), elevated histamine levels remained associated with the composite endpoint. CTP-based multivariate model adjusted sub-distribution hazard ratio (asHR): 1.010 (95% CI: 1.004-1.021), p < .001; MELD-based multivariate model asHR: 1.030 (95% CI: 1.017-1.040), p < .001.
High levels of histamine were linked to circulatory dysfunction in ACLD patients and independently associated with increased risks of ACLF or liver-related death. Further mechanistic studies on the link between histamine signalling and development of hyperdynamic circulation and ACLF are warranted.
组胺在慢性肝病晚期(ACLD)中的作用尚未明确。我们检测了 ACLD 各期患者的血浆组胺水平及其预后价值。
我们纳入了 2017 年至 2020 年间接受肝静脉压力梯度(HVPG)测量的 ACLD 患者,ACLD 的诊断标准为存在门静脉高压(HVPG≥6mmHg)和/或瞬时弹性成像测量的肝硬度≥10kPa。定义急性失代偿性肝衰竭(ACLF)和/或与肝脏相关的死亡为复合终点。
在 251 例患者中,82.5%存在临床显著的门静脉高压(HVPG 中位数:17mmHg[四分位间距(IQR)12-21]),基线时 135 例(53.8%)患者存在肝功能失代偿。血浆组胺中位数为 8.5nmol/L(IQR:6.4-11.5),37.1%的患者组胺水平升高(>9.9nmol/L)。组胺水平在 Child-Turcotte-Pugh(CTP)分期、终末期肝病模型(MELD)或 HVPG 分层中无显著差异。组胺水平与循环功能障碍标志物(如钠、肾素和醛固酮)相关。中位随访 29.2 个月期间,68 例患者发生 ACLF 或与肝脏相关的死亡。在单因素和多因素分析(校正年龄、性别、HVPG 以及 MELD、临床分期和血清白蛋白或 CTP 和血清钠)中,升高的组胺水平与复合终点仍相关。基于 CTP 的多因素模型校正亚分布风险比(asHR):1.010(95%CI:1.004-1.021),p<0.001;基于 MELD 的多因素模型 asHR:1.030(95%CI:1.017-1.040),p<0.001。
ACLD 患者中高水平的组胺与循环功能障碍有关,与 ACLF 或与肝脏相关的死亡风险增加独立相关。有必要进一步开展关于组胺信号与高动力循环和 ACLF 发生之间关系的机制研究。